Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Clinical trial NCT01925209 · COMPLETED
Trial details
- NCT number
- NCT01925209
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-26
- Primary completion
- 2016-01-06
- Enrollment
- 251
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.